Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338711 · ClinicalTrials.gov registry record · Phase 1
A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04338711 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT04338711, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetic (PK) and safety of an age-appropriate tofacitinib Modified Release (MR) formulation with varying level of enteric coating. The effect of food on the PK of age-appropriate tofacitinib MR formulation with the lowest and higher levels of enteric coating will also be assessed.
Interventions
- DRUG tofacitinib modified release (MR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2020-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04338711
The ClinicalTrials.gov registry entry for NCT04338711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tofacitinib modified release (MR) is the first listed.
NCT04338711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04338711 about?
NCT04338711 is a clinical study titled "A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations". The purpose of this study is to evaluate the pharmacokinetic (PK) and safety of an age-appropriate tofacitinib Modified Release (MR) formulation with varying level of enteric coating. The effect of food on the PK of age-appropriate tofacitinib MR formulation with the lowest and higher levels of ente...
What is the current status of trial NCT04338711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2020-06-17. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT04338711?
The interventions under investigation include: tofacitinib modified release (MR) (DRUG).
Who is sponsoring clinical trial NCT04338711?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.